Mesoblast (NASDAQ:MESO) Shares Gap Up to $5.21

Shares of Mesoblast Limited (NASDAQ:MESO) gapped up prior to trading on Monday . The stock had previously closed at $5.21, but opened at $5.39. Mesoblast shares last traded at $5.48, with a volume of 106,631 shares.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th. StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Mesoblast has an average rating of “Hold” and a consensus target price of $13.67.

Mesoblast Stock Up 8.5 %

The company has a 50 day moving average price of $3.46 and a 200-day moving average price of $2.64.

Institutional Trading of Mesoblast

A hedge fund recently raised its stake in Mesoblast stock. Lazari Capital Management Inc. grew its holdings in shares of Mesoblast Limited (NASDAQ:MESO) by 9.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 94,034 shares of the company’s stock after buying an additional 8,000 shares during the period. Lazari Capital Management Inc. owned approximately 0.06% of Mesoblast worth $116,000 as of its most recent filing with the SEC. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.